康方生物(09926)授予济川药业伊喜宁®的独家商业化权益

智通财经02-03

智通财经APP讯，康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公司(以下合称“康方生物”)与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医药有限公司(以下合称“济川药业”)于近日签署《独占性商业化权益协议》，康方生物授权济川药业在合作期限内，在中华人民共和国(不含中国香港、中国澳门特别行政区和中国台湾地区)拥有公司自主开发并...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608820376?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-03 19:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608820376","market":"us","top_or_hot":-1,"title":"康方生物(09926)授予济川药业伊喜宁®的独家商业化权益","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公司(以下合称“康方生物”)与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医药有限公司(以下合称“济川药业”)于近日签署《独占性商业化权益协议》，康方生物授权济川药业在合作期限内，在中华人民共和国(不含中国香港、中国澳门特别行政区和中国台湾地区)拥有公司自主开发并...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401164.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物(09926)授予济川药业伊喜宁®的独家商业化权益</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物(09926)授予济川药业伊喜宁®的独家商业化权益\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 19:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401164.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公司(以下合称“康方生物”)与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医药有限公司(以下合称“济川药业”)于近日签署《独占性商业化权益协议》，康方生物授权济川药业在合作期限内，在中华人民共和国(不含中国香港、中国澳门特别行政区和中国台湾地区)拥有公司自主开发并...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401164.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B543WZ88.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401164.html","article_id":"2608820376","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608820376","pubTimestamp":1770117191,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康方生物 公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公司与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医药有限公司于近日签署《独占性商业化权益协议》，康方生物授权济川药业在合作期限内，在中华人民共和国拥有公司自主开发并已获批上市的伊喜宁的独家商业化权益。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600566":"济川药业","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","BK0188":"融资融券","LU0348783233.USD":"安联东方收入型 CI A Dis美元","BK0012":"证金概念","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","BK0077":"质押式回购","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","BK0187":"一线龙头","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","09926":"康方生物","BK0028":"国家队","BK0201":"可转债","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1161":"生物科技","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","BK1574":"生物医药B类股","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK0239":"医药制造","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金"},"translate_title":"Akeso Biotech (09926) awarded Yixining to Jichuan Pharmaceutical ® Exclusive commercialization interest","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600566":1.5,"09926":1.5},"content_text":"智通财经APP讯，康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公司(以下合称“康方生物”)与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医药有限公司(以下合称“济川药业”)于近日签署《独占性商业化权益协议》，康方生物授权济川药业在合作期限内，在中华人民共和国(不含中国香港、中国澳门特别行政区和中国台湾地区)拥有公司自主开发并已获批上市的伊喜宁®(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获得由济川药业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付款;济川药业将负责伊喜宁®在授权市场的商业化推广和销售。伊喜宁®(伊努西单抗注射液)是本公司自主开发创新PCSK9单克隆抗体新药，于2024年9月获批上市，用于治疗原发型高胆固醇血症和混合型高脂血症，包括杂合子家族性高胆固醇血症(HeFH)及同时患有动脉粥样硬化性心血管疾病的高胆固醇血症。目前，伊喜宁®已被纳入最新版国家医保目录，并被全面管理血脂相关心血管风险中国专家共识(2025版)和县域血脂异常合理用药与综合管理指南(2025版)重磅推荐。伊喜宁®通过特异性结合PCSK9并阻断其与LDL-R的相互作用，恢复LDL-R的表达水平以提升对血浆中LDL-C的清除能力。既往研究表明，在他汀类药物背景治疗的基础上接受PCSK9单抗治疗可显著减少人体的胆固醇水平，降低患者心脏病发作和中风的风险。III期临床研究显示，伊喜宁®对于超高危、极高危、高危及中低危分层的患者，以及无论LDL-C情况的患者，均具有优异临床疗效，为高胆固醇血症的临床治疗、心血管风险的长期控制提供了新的选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608820376","isCrawlerRequest":true}